NCT00877500 2025-11-10
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT01349088 2025-05-02
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Thomas Jefferson University
Phase 1/2 Withdrawn
NCT03393741 2024-06-25
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
University of Wisconsin, Madison
Terminated
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00765765 2023-08-09
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00866905 2021-11-22
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01097642 2021-09-22
ICE
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01818999 2020-08-20
Ixabepilone and SBRT For Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT01084057 2019-11-05
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT00005807 2018-10-09
BMS-247550
Albert Einstein College of Medicine
Phase 1 Completed
NCT00627978 2018-06-26
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Weill Medical College of Cornell University
Phase 2 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00789581 2017-07-02
TITAN
SCRI Development Innovations, LLC
Phase 3 Completed
NCT00637897 2017-05-30
Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
Wake Forest University Health Sciences
Phase 1 Completed
NCT00998738 2016-02-04
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
Mayo Clinic
Phase 3 Terminated
NCT00821886 2014-12-22
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00825734 2014-12-22
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00751868 2014-12-17
GIM9
Consorzio Oncotech
Phase 2 Completed
NCT00924352 2014-10-13
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00020904 2013-06-18
BMS-247550 in Treating Women With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00790894 2011-05-18
HIT
Hellenic Cooperative Oncology Group
Phase 2 Terminated